Alterity Therapeutics Limited, a development stage enterprise, has entered into a Sales Agreement with JonesTrading Institutional Services LLC on February 15, 2024. Under this agreement, Alterity Therapeutics may issue and sell American Depositary Shares (ADSs) through JonesTrading, which will act as the sales agent. The sales are to be conducted on an 'at the market offering' basis, as defined by Rule 415 of the Securities Act Regulations. JonesTrading will receive a 3% commission on the gross sales price of the shares sold. The ADSs will be offered up to a total of US$6,000,000, and this offering is pursuant to a Prospectus Supplement filed with the Securities and Exchange Commission on the same date. The shares will be issued under the company's effective Registration Statement on Form F-3. The company's counsel has provided an opinion on the validity of the shares to be issued, which is included as an exhibit in the report.

Alterity Therapeutics Limited, a development stage enterprise, has entered into a Sales Agreement with JonesTrading Institutional Services LLC on February 15, 2024. Under this agreement, Alterity Therapeutics may issue and sell American Depositary Shares (ADSs) through JonesTrading, which will act as the sales agent. The sales are to be conducted on an 'at the market offering' basis, as defined by Rule 415 of the Securities Act Regulations. JonesTrading will receive a 3% commission on the gross sales price of the shares sold. The ADSs will be offered up to a total of US$6,000,000, and this offering is pursuant to a Prospectus Supplement filed with the Securities and Exchange Commission on the same date. The shares will be issued under the company's effective Registration Statement on Form F-3. The company's counsel has provided an opinion on the validity of the shares to be issued, which is included as an exhibit in the report.